Over the last decade, several studies have explored the efficacy and safety of biologic agents in SS and after the failure of tumour necrosis factor-α inhibitors, there has been a considerable and concerted effort to develop drugs that target different components of the canonical TGF-β signalling pathway. Here, TGFB1 is linked to synovial sarcoma.